Sector News

BioAmber Announces New Chief Financial Officer and Change to the Board

January 7, 2015
Life sciences
/PRNewswire/ – BioAmber Inc., an industrial biotechnology company producing sustainable chemicals, today announced that Chief Financial Officer Andrew Ashworth retired on December 31, 2014 and Francois Laurin has been hired to succeed Andrew as the Company’s Chief Financial Officer.  BioAmber also announced today that long-time board member Denis Lucquin had resigned effective December 31, 2014. 
 
Andrew Ashworth is retiring after three and a half years as BioAmber’s CFO, the culmination of a long and distinguished career that previously included senior positions at Genencor/Danisco and VF Corporation.  Andrew was instrumental in preparing BioAmber for its initial public offering, completing the IPO in 2013 and ensuring regulatory compliance since the listing.  Andrew will continue in an advisory role to the Company in the first half of 2015 to ensure a smooth transition.
 
Francois Laurin has been hired to succeed Andrew as Chief Financial Officer.  Francois was most recently the CFO of Alderon Iron Ore Corp (NYSE:AXX, TSX:ADV), a publicly listed exploration and development stage company in the mining sector.  Francois was formerly the CFO of Consolidated Thompson Iron Mines (TSX:CLM), where he played a leading role in the rapid growth of the company and its subsequent sale to Cliffs National Resources for $4.9 billion and prior to that he was the CFO of Transat A.T. (TSX:TRZ).  Francois has also held senior financial positions at Caisse de Depot du Quebec, Bombardier and Teleglobe.  Francois is a chartered professional accountant and a chartered financial analyst, and was named a Fellow CPA in 2014.
 
“Andy has been a valued colleague who’s extensive experience helped guide our IPO efforts.  He will be missed and we wish him the best in his retirement,” said JF Huc, BioAmber CEO.  “I am pleased to welcome Francois Laurin, a seasoned, dynamic CFO with extensive public company experience.  He is a great addition and will help lead BioAmber through our next stage of growth,” he added.
 
Denis Lucquin is the Managing Partner of Sofinnova Partners, a European venture capital firm that led the original investment in BioAmber in 2009.  Denis has been a board member since Sofinnova’s initial investment and he has greatly contributed to the Company’s success.  Denis’ decision to resign was due to his firm’s policy to step down from board memberships following initial public offerings. 
 
“On behalf of the board, I’d like to thank Denis for his many contributions.  His experience in funding start ups and his industry knowledge proved invaluable in guiding BioAmber from a four person start up to a publicly traded company,” said Raymond Land, chairman of the board. 
 
“I am proud to have helped BioAmber become the company it is today, which I believe is on the verge of success in the emerging field of bio-based chemicals,” said Denis Lucquin.
 
Source: BioAmber 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach